



Probiotics in Crohn's disease remission: a systematic review

Kamilla Pontes Azevedo¹ , Maria Zilda de Jesus Catulio¹ , Rávila Graziany Machado de Souza² ,
Maria Luiza Ferreira Stringhini¹ .

Abstract: Probiotics in Crohn's disease remission: a systematic review. Introduction. Crohn's disease (CD) is an inflammatory condition that can affect the entire gastrointestinal tract due to an exacerbated and inadequate immune system response. **Objective.** This study aimed to conduct a systematic review, through clinical trials, about the use of probiotics in humans with CD. **Materials and methods.** Research was carried out in the PubMed, Scopus and Science Direct databases using the keywords “Crohn's disease” and “probiotics”. We conducted the review by searching clinical trials published from 2000 to December 2019. **Results.** Of 2,164 articles found, only nine were considered eligible for this review. The studies investigated patients with CD at different stages of the pathology, and in three studies the potential effect of probiotics in the active phase was observed; in two, in the remission phase; and in four, after intestinal surgery. The sample size of the studies ranged from 11 to 165 individuals and the age of the participants between 5 and 71 years. Gram-positive bacteria were used in six clinical interventions and in two studies yeasts were used. As for the significant results obtained with the treatment with probiotics, in one study there was beneficial clinical effects in patients and, in another, there was an improvement in intestinal permeability. **Conclusion.** Currently, it is not possible to establish a recommendation for probiotic therapy to control CD due to the few clinical trials with significant results. There is a need for more research on clinical intervention with probiotics in CD to clarify the action, define doses and time of use. **Arch Latinoam Nutr 2022; 72(1): 50-59.**

Keywords: Crohn disease, ulcerative colitis, intestinal mucosa, probiotics.

Resumo: Probióticos en la remisión de la enfermedad de Crohn: una revisión sistemática. Introducción. La enfermedad de Crohn (EC) es una afección inflamatoria que puede afectar todo el tracto gastrointestinal debido a una respuesta del sistema inmunitario exacerbada e inadecuada. **Objetivo.** Realizar una revisión sistemática, a través de ensayos clínicos, sobre el uso de probióticos en humanos con EC. **Materiales y métodos.** La investigación se realizó en las bases de datos PubMed, Scopus y Science Direct utilizando las palabras clave “enfermedad de Crohn” y “probióticos”. La revisión se hizo en ensayos clínicos publicados desde 2000 hasta diciembre 2019. **Resultados.** De 2164 artículos encontrados, solo nueve fueron considerados elegibles. Los estudios investigaron pacientes con EC en diferentes etapas de la patología, y en tres estudios se observó el efecto potencial de los probióticos en la fase activa; en dos, en remisión; y en cuatro, tras cirugía intestinal. El tamaño de la muestra fue entre 11 y 165 individuos y la edad entre 5 y 71 años. Se utilizaron bacterias grampositivas en seis intervenciones clínicas y en dos estudios se utilizaron levaduras. En cuanto a los resultados significativos obtenidos con el tratamiento con probióticos, en un estudio hubo efectos clínicos beneficiosos en los pacientes y, en otro, hubo una mejora en la permeabilidad intestinal. **Conclusión.** Actualmente, no es posible establecer una recomendación de terapia con probióticos para el control de la EC debido a los pocos ensayos clínicos con resultados significativos. Existe la necesidad de más investigación sobre la intervención clínica con probióticos en EC para aclarar la acción, definir dosis y tiempo de uso. **Arch Latinoam Nutr 2022; 72(1): 50-59.**

Palabras clave: enfermedad de Crohn, colitis ulcerativa, mucosa intestinal, probióticos

Introduction

Inflammatory bowel diseases (IBD), of autoimmune origin, are characterized by systemic changes of chronic inflammatory character resulting from excessive and inadequate response of the immune system related to the gastrointestinal tract, among which the most common is

¹Universidade Federal de Goiás, Faculdade de Nutrição, Goiás, GO, Brasil.

² UniEvangélica – Centro Universitário de Goiás, Goiás, GO, Brasil.

Autor para la correspondencia: Maria Luiza Ferreira Stringhini, E-mail: mluizastring@uol.com.br

Crohn's disease (CD) (1). In a systematic review of population-based study described by Ng *et al.* (2), published in 2017, the prevalence of CD in Europe ranged from 1.51, in Romania, to 322.0 per 100000 inhabitants in Germany. In Brazil, reliable data on the incidence and prevalence of Crohn's disease is scarce because IBD is not a mandatory notifiable disease. Thus, public registries and adequate records are limited, resulting in the conduct of regional epidemiological studies (3). In view of this scenario, a study carried out in mid western region of São Paulo State, Brazil, CD prevalence is of 14.8 cases per 100 000 inhabitants (4). In a more recent study, Gasparini *et al.* (5) estimated that prevalence of CD in the State of São Paulo from January 2012 to December 2015 was 24.3 cases/100 000 inhabitants. Ng *et al.* (2) noticed that, since 1990, the incidence has been rising in newly industrialized countries in Africa, Asia, and South America, including Brazil with 3.5 per 100 000 person-years, in São Paulo State.

CD affects any segment of the gastrointestinal tract with predominance in the region of the rectum, colon, and ileum in an asymmetric, segmental, and transmural manner, being marked by periods of remissions and activations, affecting mainly the second and third decades of life. It occurs mainly in the inflammatory, fistulous, and fibrostenosing form with possible extra intestinal evolution of ophthalmological, dermatological and rheumatological involvement. As the main symptoms are abdominal pain, diarrhea, fatigue, fever, intestinal obstruction, nausea, vomiting and weight loss impairing the patient's quality of life (1).

The development of CD has no definite cause, having a multifactorial nature from the interaction of environmental, genetic and immunological factors (6). Among the changeable risk factors is the intestinal microbiota, which has a mutualism relationship with the human being, when in balance. This microbiota is defined as a complex cluster of bacterial colonies that populate the human gastrointestinal tract (7). The amount, type and activity of bacteria that make up these colonies can be modulated by environmental factors such as

mode of delivery, health conditions, food, use of antibiotics and smoking, which are also linked to the development of CD, since they alter intestinal homeostasis (8).

From the analysis of the microbiota, it is possible to observe a direct relationship between the colonies in the bowel and the immunological activity of the host. The imbalance of these microorganisms, known as dysbiosis, may generate a pro-inflammatory state with changes in motility and increased intestinal permeability, which leads to the development of metabolic, neoplastic or autoimmune diseases, such as CD (9).

The protective role of the intestinal microbiota in the host is due to the adequate intestinal colonization (10). Thus, possible forms of modulation are described, among which the use of probiotics has been widely investigated. Probiotics are defined as live microorganisms that, when administered in an appropriate concentration, can provide benefit to the consumer, either through local competition, antagonistic action or immunological modulation (10).

Research has been carried out for years in the hope of finding alternatives for prolonging the period of CD remission. Among the clinical trials conducted with the use of probiotics, the results indicate an ambiguous scenario, in which they may decrease the inflammatory response or do not have any beneficial effect for patients with CD (11).

In view of the above and reflecting on this theme, the motivation for this work emerged. Thus, this qualitative systematic review aims to assess the scientific evidence of the effectiveness of therapeutic interventions with probiotics in patients with CD.

Materials and Methods

Research strategy

This review was conducted, between March to December 2019, using the "Preferred Reporting Items for Systematic Reviews and Meta-Analysis" (PRISMA) and it is registered in "International Prospective Register of Systematic Reviews" (PROSPERO) under number CRD42020132579.

This qualitative systematic review was carried out in the Medline (PubMed), Scopus and ScienceDirect databases. We conducted the review by searching clinical trials published

from 2000 to December 2019. The following descriptors, using Medical Subject Headings (MeSH) “Crohn's disease” and “probiotics” were associated with the Boolean operator “and” to support the search strategy and combine the terms. Reference lists of relevant articles were manually searched identify new studies. Only studies written in English were selected. The search strategy and the total of studies evaluated and selected are shown in Figure 1.

Article's selection

Two independent reviewers performed the review of titles and abstracts. The initial review consisted of a screening of titles and abstract, with subsequent full reading of the work, exclusion of duplicate articles or those which did not meet the proposed inclusion criteria. Discrepancies were discussed

through consultation with a third reviewer. Randomised controlled trials that compared probiotics with placebo or any other non-probiotic intervention in humans, children, adolescents and adults, original works who analyzed the use of probiotics in modulating the intestinal microbiota or who evaluated the efficacy and safety of probiotics in inducing remission in Crohn's disease were considered. The following articles were excluded: animal studies, case reports, reviews, and editorials.

Data extraction

The following variables were extracted from each study: first author; year of publication; goals; design; sample size; strains and colony forming




Figure 1. Flowchart of the selection of studies for inclusion in the systematic review.

units (CFU), time of intervention and results related to clinical, biochemical, and immunological improvement of patients.

Results

This qualitative systematic review selected nine articles that met the previously established criteria (11-19). All articles were randomized, double-blind and placebo-controlled, with follow-up time between 3 and 24 months, of which five were multicentric (11-15). There was a regular temporal distribution of articles related to clinical intervention with the use of probiotics from the year 2000 to 2015, with a focus in the period of CD remission, through the control of signs and symptoms intrinsic to the pathology. Between 2015 to 2019 no clinical intervention was found that comply with the inclusion criteria.

The studies investigated patients with CD at different stages of the disease, and in two studies the potential effect of probiotics in the active phase (16,17) was evaluated, three in the remission phase (11,12,18) and in four studies, patients after intestinal surgery (13-15,19) were analyzed. No studies were found relating probiotics to modulation of the intestinal microbiota. The sample size of the

studies ranged from 11 to 165 individuals and the age of the participants ranged from 5 to 71 years.

Gram-positive bacteria were used in six clinical interventions and in three studies yeasts were used (Table 1). *Lactobacillus rhamnosus* stripe GG were used in three clinical trials (12,16,19); *Lactobacillus johnsonii* LA1(13,14) in two; and in one there was an association of eight different bacteria (*Lactobacillus* – *L. praeacaei* DSM24733, *L. plantarum* DSM24730, *L. acidophilus* DSM24735 and *L. delbrueckii* subsp *bulgaricus* DSM24734; *Bifidobacterium* – *B. longum* DSM24736, *B. breve* DSM24732 and *B. infantis* DSM24737 and *Streptococcus salivarius* subsp *thermophilus* DSM24731)(15). The authors used *Saccharomyces boulardii* as probiotic in three research papers (11,17,18). In the research by Bousvaros *et al.* (12) inulin was also used, together with the probiotic.

As for the positive results obtained in therapy with probiotics, it was found that in the study by Guslandi *et al.* (18), there was a significant reduction in clinical relapses, after six months, on patients receiving *Saccharomyces boulardii* (1 g / day) together with mesalamine (2 g/d) (p=0,04). In another clinical intervention carried out by Vilela *et al.* (17), the same yeast contributed to a significant reduction in the lactulose / mannitol ratio and increased the function of the intestinal barrier. Other clinical trials in this systematic review did not find significant results, especially in the rate of recurrences, among the groups that used probiotics and placebo (Table 1).

Table 1. Characteristics of studies regarding the intervention of probiotics in Crohn's disease.

Authors and year of publication	Objectives	Outline	Sample	Probiotic, colony forming units (CFU) or mg / day	Intervention time	Results
Guslandi <i>et al.</i> (18)	To evaluate the therapeutic benefits of probiotics in the treatment of adults in the remission phase of CD.	Randomized double-blind, placebo-controlled study.	32 (male / female 20/12, aged 23 to 49 years).	<i>Saccharomyces boulardii</i> (1 g/day).	6 months	Clinical relapses at six months were observed in 6 of the 16 patients on standard mesalamine maintenance and in 1 of the 16 patients receiving also <i>Saccharomyces boulardii</i> (p=0.04).
Prantera <i>et al.</i> (19)	To assess the effectiveness of the probiotic on clinical or endoscopic recurrence or on the reduction of the severity of lesions after one year of surgery.	Randomized double-blind, placebo-controlled study.	45 (male / female 29/16, aged 22 to 71 years).	<i>Lactobacillus rhamnosus</i> GG (12x10 ⁹ UFC/day).	12 months	Nine of the 15 patients in the intervention group had recurrent endoscopic lesions compared with six of the 17 patients in the placebo group (p = 0.297). There were no significant differences in the severity of injuries between groups.

Table 1. Characteristics of studies regarding the intervention of probiotics in Crohn's disease. (Continuation)

Authors and year of publication	Objectives	Outline	Sample	Probiotic, colony forming units (CFU) or mg / day	Intervention time	Results
Schultz <i>et al.</i> (16)	To determine the effect of oral probiotic intake on induction and maintenance medically remission.	Randomized double-blind, placebo-controlled study.	11 (gender and age of participants were not reported).	<i>Lactobacillus rhamnosus GG</i> (2x10 ⁹ UFC/day).	6 months	The mean time to relapse was 16 ± 4 weeks in the group that used probiotics and 12 ± 4.3 weeks in the placebo group (p = 0.5). CDAI and C-reactive protein were not significantly changed in both groups.
Bousvaros <i>et al.</i> (12)	To evaluate if the addition of probiotics to standard therapy prolonged remission in children and adolescents with CD.	Multicenter randomized double-blind, placebo-controlled study.	75 (male / female 47/28, aged 5 to 21 years).	<i>Lactobacillus rhamnosus GG</i> (1x 10 ¹⁰ UFC) associated with 295 mg of inulin, twice daily.	2 years	The recurrence was 9.8 months in the intervention group and 11.7 months in the placebo group (p = 0.24); 31% of the patients in the intervention group had recurrences and 17% in the placebo group (p = 0.18).
Marteau <i>et al.</i> (13)	To demonstrate the effectiveness of the probiotic on the endoscopic recurrence rate after intestinal surgery	Multicenter randomized double-blind, placebo-controlled study.	98 (male / female 47/51, aged 27 to 42 years).	<i>Lactobacillus johnsonii</i> (LA1) (2x10 ⁹ UFC), twice daily.	6 months	The endoscopic score did not differ between the intervention and placebo groups (p = 0.15). Severe endoscopic recurrence was observed in 21% of patients in the intervention group. The treatment effect was not modified when adjusted for smoking habit (p = 0.12), CRP value (p = 0.15) or type of resection (p = 0.24).
Van Gossum <i>et al.</i> (14)	To evaluate the safety and efficacy of probiotic in preventing endoscopic recurrence after ileocecal resection in patients with CD.	Multicenter randomized double-blind, placebo-controlled study.	70 (male / female 37/33, mean age of 37 + 13 years).	<i>Lactobacillus johnsonii</i> (LA1) (1x 10 ¹⁰ UFC/day).	3 months	The endoscopic score was not significantly different between groups (p = 0.48). Patients with severe recurrence was 21% in the intervention group and 15% in the placebo (p = 0.33). CDAI was not different between groups (p = 0.79) and either the CRP levels (p = 0.13).
Vilela <i>et al.</i> (17)	To evaluate the influence of probiotics on intestinal permeability in patients with CD.	Randomized double-blind, placebo-controlled study.	31 (male / female 18/13, aged 19 to 54 years).	<i>Saccharomyces boulardii</i> - 17(4x10 ⁸ UFC three times daily).	3 months	In the intervention group, a significant decrease in the lactulose/mannitol rate was observed (p = 0.0005). Probiotic, added to baseline therapy, improved intestinal barrier permeability, even though complete normalization was not achieved.
Bourreille <i>et al.</i> (11)	To assess the effects of probiotics in patients with CD during remission with steroid or aminosalicylate therapy.	Multicenter randomized double-blind, placebo-controlled study.	159 (male / female 45/114, with mean age in the intervention group of 37.9 + 14.2 years and in the placebo group, 35.9 + 13.2 years).	<i>Saccharomyces boulardii</i> (1,000 mg /day)	52 weeks	The mean time to recurrence interval was not different between patients in the intervention and placebo group, 40.7 (2.6–56.0) vs 39.0 (0.1–55.0) weeks (p = 0.78), respectively. The percentage of relapses during the weaning period of the initial treatment was similar in both groups (p = 0.26). There was no difference between groups in the CDAI, erythrocyte sedimentation rate and C-reactive protein values.

Table 1. Characteristics of studies regarding the intervention of probiotics in Crohn's disease. (Continuation)

Authors and year of publication	Objectives	Outline	Sample	Probiotic, colony forming units (CFU) or mg / day	Intervention time	Results
Fedorack <i>et al.</i> (15)	To analyze the probiotic's ability to prevent CD recurrence in patients undergoing intestinal resection.	Multicenter randomized double-blind, placebo-controlled study.	120 (male / female 62/58, with mean age in the intervention group of 37.6 + 12.4 years and in the placebo group, 35.9 + 11.8 years)	VSL#3 (9x10 ¹⁰ UFC) (<i>Lactobacillus</i> – <i>L. prasei</i> DSM24733, <i>L. plantarum</i> DSM24730, <i>L. acidophilus</i> DSM24735 e <i>L. delbrueckii subsp bulgaricus</i> DSM24734; <i>Bifidobacterium</i> – <i>B. longum</i> DSM24736, <i>B. breve</i> DSM24732 e <i>B. infantis</i> DSM24737 e <i>Streptococcus salivarius subsp thermophilus</i> DSM24731).	12 months	Patients receiving probiotics within 30 days after surgery demonstrated no significant reduction in endoscopic recurrence and cytokine levels compared with placebo after 90 days. CDAI end points were similar in both groups. Although not significant, the group that received probiotics for entire 365 days had reduction in endoscopic recurrence compared to the group that received the probiotic from day 90 to 365.

Discussion

This review included nine clinical trials conducted between the years 2000-2019, aiming to analyze the role of probiotics in the treatment of CD. The results of seven of these studies attested the ineffectiveness of the probiotic therapy adopted to prolong remissions or improve signs and symptoms. It was possible to find points of convergence between the studies by Prantera *et al.* (19) and Schultz *et al.* (16), whose research field was the use of the probiotic strain *Lactobacillus GG* in the gastrointestinal tract of adult CD patients, but with different time, concentration, and association with other drug therapies. However, such factors did not influence the result found, since in both studies there was no prolongation of remission and / or improvement of injuries when compared to the control group.

Still concerning the investigation of the efficacy of the use of *Lactobacillus GG* in CD, a multicenter study was carried out in 2005 with young people and children in remission of the disease for at least two months using amino salicylates, azathioprine or corticosteroids in low doses. However, the results obtained also indicated that the mean time to recurrence was similar in both the intervention and control groups (12).

As for the studies that analyzed the modulation capacity of the intestinal microbiota using *Lactobacillus GG*, it appears that none reached its objective in proving the probiotic's effectiveness in prolonging the remission time of CD, in different stages of the disease. In the study by Prantera *et al.* (19), for example, it would be necessary to consider the largest number of smokers in the intervention group, but without statistical difference in relation to the placebo group. The same was verified in the population studied by Marteau *et al.* (13), in which there was a greater presence of smokers or ex-smokers in the group receiving the probiotic. It is noteworthy that in both studies, smoking was not considered an exclusion factor to participate in the clinical trial.

It is known that smoking is one of the environmental factors responsible for the increase in immunosuppressants, being able to alter endothelial function with impairment of mucosal integrity and to modify the intestinal microbiota, in addition to increasing oxidative stress through the activation of monocytes and macrophages, which

release pro-inflammatory cytokines such as IL-6 and TNF- α (20). Thus, the inclusion of smokers in the study group could negatively influence the results regarding the effect of using probiotics in the studies by Prantera *et al.* (19) and Marteau *et al.* (13).

In the work by Bousvaros *et al.* (12), the presence of inulin in the capsules of both the intervention group and the placebo group could contribute to significant results related to the recurrence of CD, which were not verified. Inulin is a polymer of fructose present in many vegetables. As a functional ingredient, it is a prebiotic capable of influencing the intestinal microbiome, selectively promoting the growth of bacteria native to the digestive tract by producing a range of short-chain fatty acids that lower the overall pH of the digestive system, preventing colonization by pathogens (21).

In the essay by Schultz *et al.* (16), the small sample size ($n = 11$) and the short intervention period (six months) are the warning points. The authors reported that, due to the low inclusion rates of patients and the negative effects of the probiotic on CD remission, the study was early interrupted. Another difficulty observed in this clinical trial is related to the methodology, which does not clarify the placebo composition. In the end, they concluded that *Lactobacillus rhamnosus GG* did not induce nor allow the induction of medications (corticosteroids) to improve the CD Activity Index.

Guslandi *et al.* (18), Vilela *et al.* (17) and Bourreile *et al.* (11) had as common premise the effectiveness analysis of the yeast *S. boulardii* in the treatment and maintenance of CD remission; however, in the methodology they used time, number of participants, probiotic concentration and association with different drug therapies. The authors possibly used *S. boulardii* because it is a probiotic yeast with beneficial effects on the intestinal epithelial barrier and on the digestive immune system, since it acts by inhibiting the growth of pathogenic bacteria, as already discussed in the literature (22).

Guslandi *et al.* (18) found a possible beneficial association of probiotic therapy. However, unlike the other studies, this one associated the yeast *S.*

boulardii (1g / day) with mesalamine (2g / day) and, after six months, the remission was measured through a reduction in the Crohn's disease activity index (CDAI) (data not shown). The disease is in remission when the CDAI is less than 150; mild to moderate when it oscillates between 150 and 219; moderate to severe between 220 and 450; and severe or fulminating when the values are greater than 450 (1). Another discussion of this study is that, in the intervention group, the dose of mesalazine (2 g/d) was lower than in the placebo group (3 g/d) and this fact introduced an uncontrolled variable that could modify the results of the intervention group.

Vilela *et al.* (17) observed an improvement in intestinal permeability when associating *S. boulardii* with standard therapy (mesalamine, azathioprine, prednisone, metronidazole and thalidomide) used by patients; however, differently from other studies, this one evaluated the improvement by using the lactulose/mannitol ratio test. This analysis consists of the administration of lactulose and mannitol, through oral overload, and the determination of both substances in the urine, by high-performance liquid chromatography, informing the percentage of absorption and, consequently, intestinal integrity and absorptive function (23).

Mannitol is a monosaccharide that, in normal situations, is absorbed between 5 and 30 %. Its analysis informs the degree of absorption of small molecules (<0.4 nm) by transcellular route. Lactulose, on the other hand, is a disaccharide that must be absorbed at levels below 0.5 % and its determination indicates the degree of absorption of large molecules (> 0.5-0.6 nm) by paracellular route. So, an increase in lactulose recovery reflects an increase in paracellular permeability (between cells), which allows toxins, antigens, peptides or even macromolecules to cross the intestinal barrier (23).

The calculation of the larger marker/smaller marker ratio reduces individual variation caused by factors such as gastric emptying, intestinal transit, and difficulty in collecting urine and increases the accuracy in the evaluation of intestinal permeability (23). Also, lactulose/mannitol ratio permits a more precise and sensitive monitoring of the therapeutic response than clinical observation in patients with CD, since these tests can detect repercussions of alterations intimately associated with the inflammatory processes present in the disease (17).

Continuing the analysis of the effectiveness of *S. boulardii*, the study by Bourreile *et al.* (11) evaluated patients after treatment with corticosteroids (systemic or topical) and

salicylates, so that it was not possible to notice positive results related to this probiotic therapy in patients. According to Veauthier and Hornecker (1), corticotherapy reduces inflammation through the glucocorticoid receptor. Within the cell, cortisol, in combination with the receptor, is associated with transcription factors, such as the nuclear factor κ B, with a reduction in the production of inflammatory proteins. This factor was also elucidated by Lamb *et al.* (24), who established corticosteroids and amino salicylates as effective drug therapies in the treatment of IBD, such as CD.

In the same study by Bourreile *et al.* (11), the probiotic was administered to patients with different smoking habits. In this case, the habit of not smoking favored the results of patients with CD who received *S. boulardii* to the detriment of those who received the placebo, with no difference in the time of relapse of the disease between smokers and ex-smokers even with the administration of the probiotic.

Thus, it is observed that most clinical trials in this review failed to establish a cause-effect relationship between the attenuation and remission of CD caused by the administration of the probiotic. Among other factors, the use of various drugs to control the disease, the difference in location and disease activity in patients allocated to each group, as well as the limited number of individuals in the intervention and control group may have affected the results.

In addition to these aspects, the studies carried out did not observed changes in increasing the diversity and abundance of beneficial microbial species using probiotics, which requires genetic sequencing for the complete determination of the intestinal microbiota. It is known that this microbiota is extremely important for the maintenance of the health of the host; however, so far it has not been described whether changes in the intestinal flora would be a consequence or cause of diseases and the mechanisms of this modulating role still need to be better understanding (25).

Another factor to be considered is that in none of these surveys there was a report on the participants' diet. According to Reddavid *et al.* (26), foods such as vegetables and fruits, abundant in fibers and micronutrients (antioxidants and anti-inflammatories), help to reduce inflammation in the mucosa and maintain the function of the intestinal barrier, helping to delay symptoms CD and other IBD. According to the current guidelines, in the treatment of IBD the food groups mentioned by the author are recommended and may decreased intestinal permeability (27). It is known that there is no diet that can

be generally recommended to promote remission in IBD patients with active disease and no specific diet needs to be routinely followed during remission phases of CD (27). However, it would be important to control patients' diet in researches.

We are still far from fully translating this research into clinical and therapeutic treatment applied to IBD. Studies that relate probiotic therapy with the purpose of increasing the time of remission of CD have as limiting factors the lack of control of the participants' diet; the use of *Saccharomyces boulardii* and *Lactobacillus* as probiotics only and the results cannot be extrapolated to other strains or dosages; the different numbers of colony forming units and treatment time. In addition, since the CDAI is not, currently, considered a good parameter for measuring intestinal inflammation, we suggest incorporating other parameters such as endoscopy, magnetic resonance imaging, US Doppler and calprotectin, among others, in future studies to characterize possible changes in the mucosa intestinal by probiotics. All authors agree with the need for other clinical trials, especially to clarify the mechanisms of action of probiotics and the factors of the digestive ecosystem that can influence this performance. Such clarifications should allow to optimize the use of probiotics in the treatment of patients with IBD. The available evidence is very uncertain about the efficacy of probiotics for induction of remission in Crohn's disease.

Conclusion

Despite the possible evidence related to probiotic therapy in the remission of CD, only two intervention studies carried out, to date, prove the effectiveness of its use in remission or in the clinical improvement. The data are still insufficient and the results confusing. These facts have led to a failure to define the appropriate probiotic treatment for DC suggesting that well-designed randomized control trials are needed for future research. Furthermore, a better understanding of the gut microbiome will also determine the role of probiotics as therapeutic agents in the management of IBD.

Conflict of interest

We declare that there is no conflict of interest.

Referencias

1. Veauthier B, Hornecker JR. Crohn's Disease: Diagnosis and Management. *Am Fam Physician*. 2018;98(11):661-669.
2. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. World wide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2017;390(10114):2769-78. Available in: [http://doi.org/10.1016/S0140-6736\(17\)32448-0](http://doi.org/10.1016/S0140-6736(17)32448-0).
3. Quaresma AB, Kaplan GG, Kotze PG. The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil. *Curr Opin Gastroenterol* 2019; 35:259-264. Available in: <http://doi.org/10.1097/MOG.0000000000000534>.
4. Victoria CR, Sassak LY, Nunes HRC. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. *Arq. Gastroenterol.* [online]. 2009;46(1):20-25. Available in: <https://doi.org/10.1590/S0004-28032009000100009>.
5. Gasparini RG, Sassaki LY, Saad-Hossne R. Inflammatory bowel disease epidemiology in São Paulo State, Brazil. *Clin Exp Gastroenterol* 2018; 11:423-429. Available in: <http://doi.org/10.2147/CEG.S176583>.
6. Crowley E, Muise A. Inflammatory Bowel Disease: What Very Early Onset Disease Teaches Us. *Gastroenterol Clin North Am*. 2018;47(4):755-772. Available in: <http://doi: 10.1016/j.gtc.2018.07.004>.
7. Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. *Gastroenterology* 2019;157:647-659.
8. Barbosa BA. Fatores ambientais associados ao desenvolvimento de Doença Inflamatória Intestinal [dissertação]. Porto: Universidade do Porto, Instituto de Ciências Biomédicas Abel Salazar, Mestrado Integrado em Medicina; 2015-2016. 34 p.
9. Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, et al. Pathophysiology of Crohn's disease inflammation and recurrence. *Biol Direct*. 2020;15(1):23. Available in: <https://doi.org/10.1186/s13062-020-00280-5>.
10. Wieërs G, Belkhir L, Enaud R, Leclercq S, Philippart de Foy JM, Dequenne I, et al.. How Probiotics Affect the Microbiota. *Front Cell Infect Microbiol*. 2020;9:454. Available in: <https://doi.org/10.3389/fcimb.2019.00454>.
11. Bourreille A, Guillaume C, Girad LD, David L, Laurent B, Jean Louis D, et al. *Saccharomyces boulardii* does not prevent relapse of Crohn's disease. *Clin Gastroenterol Hepatol*. 2013;11:982-7.
12. Bousvaros A, Guadalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, et al. A Randomized, double-blind trial of *Lactobacillus GG* versus placebo in addition to standard maintenance therapy for children with Crohn's disease. *Inflamm Bowel Dis*. 2005;11(9):833-9.
13. Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of *Lactobacillus johnsonii* LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. *Gut*. 2006;55(6): 842-7.
14. Van Gossum A, Dewit O, Louis E, Hertogh G, Baert F, Fontaine F, et al. Multicenter randomized-controlled clinical trial of probiotics (*Lactobacillus johnsonii*, LA1) on early endoscopic recurrence of Crohn's disease after ileo-cecal resection. *Inflamm Bowel Dis*. 2007;13(2):135-42.
15. Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. *Clin Gastroenterol Hepatol* 2015;13(5):928-35.e2.
16. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. *Lactobacillus GG* in inducing and maintaining remission of Crohn's disease. *BMC Gastroenterol*. 2004;4:5. Available in: <https://doi.org/10.1186/1471-230X-4-5>.
17. Vilela EG, Ferrari MLA, Torres HOG, Pinto AG, Aguirre ACC, Martins FP, et al. Influence of *Saccharomyces boulardii* of the intestinal permeability of patients with Crohn's disease in remission. *Scand J Gastroenterol*. 2008;43(7):842-8.
18. Guslandi M.; Mezzi G.; Sorghi M.; Testoni P. A. *Saccharomyces boulardii* in maintenance treatment of Crohn's disease. *Dig Dis Sci*. 2000;45(7):1462-4.
19. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with *Lactobacillus GG*. *Gut*. 2002;51(3): 405-9.
20. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. *Dis Mon*. 2018;64(2):20-57.
21. Ahmed W, Rashid S. Functional and therapeutic potential of inulin: A comprehensive review. *Crit Rev Food Sci Nutr*. 2019;59(1):1-13. Available in: <https://doi.org/10.1080/10408398.2017.1355775>.
22. Oh GM, Moon W, Seo KI, Jung K, Kim JH, Kim SE, et al. Changes in the Crohn's Disease Activity Index and Safety of Administering *Saccharomyces Boulardii* in Patients with Crohn's Disease in Clinical Remission: A Single Hospital-based Retrospective Cohort Study. *Korean J Gastroenterol*. 2020;76(6):314-21. Available in: <https://doi.org/10.4166/kjg.2020.115>. PMID: 33250507.

23. Ataliba,GS. Avaliação da influência na barreira intestinal, por meio do teste de permeabilidade e dosagem de calprotectina fecal, em pacientes com doença de crohn, em resposta ao tratamento com terapia biológica (anticorpos anti-tnf alfa) [dissertação]. Belo Horizonte: Universidade Federal de Minas Gerais, Programa de PósGraduação em Ciências Aplicadas à Saúde do Adulto, área de concentração Ciências Aplicadas ao Aparelho Digestivo, Faculdade de Medicina; 2015. 73 p.
24. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, *et al.* British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*. 2019; 68(Suppl 3):s1-s106. Available in: <https://doi.org/10.1136/gutjnl-2019-318484>.
25. Shang Q. From correlation to causation: The missing point in the study of functional foods and gut microbiota. *J Funct Foods*. 2019;61: 103466. Available in: <https://doi.org/10.1016/j.jff.2019.103466>
26. Reddavid R, Rotolo O, Caruso MG, Stasi E, Notarnicola M, Miraglia C, Nouvenne A, Meschi T, De' Angelis GL, Di Mario F, Leandro G. The role of diet in the prevention and treatment of Inflammatory Bowel Diseases. *Acta Biomed*. 2018;89(9-S):60-75. Available in: <https://doi.org/10.23750/abm.v89i9-S.7952>.
27. Forbes A, Escher J, Hébuterne X, Klek S, Krznaric Z, Schneider S, *et al.* ESPEN guideline: Clinical nutrition in inflammatory bowel disease. *Clin Nutr*. 2017;36(2):321-47.

Recibido: 12/05/2021
Aceptado: 10/12/2021